TABLE 1.
Long‐term survivors with complete remission who were initiated on intensive chemotherapy between July 2000 and October 2016
| Treatment regimen | N |
|---|---|
| VCAP‐AMP‐VECP (mLSG15) | 34 |
| CHOP‐like | 3 |
| Number of patients | Sex | Age at diagnosis | Subtype of ATLL | Survival after starting chemotherapy (months) | CD4/CD8 reversal | Herpes virus infection | HLA |
|---|---|---|---|---|---|---|---|
| 1 | Male | 69 | Lymphoma | >221 | + | + | A*02:01 |
| 2 | Male | 68 | Lymphoma | >211 | + | + | A*02:01 |
| 3 | Female | 62 | Lymphoma | >177 | + | − |
A*02:01 A*24:02 |
| 4 | Female | 61 | Acute | >125 | + | − |
A*02:01 A*24:02 |
| 5 | Female | 71 | Lymphoma | 71 | + | − | N.E. |
| 6 | Male | 60 | Lymphoma | >192 | + | + | N.E. |
Abbreviations: ATLL, adult T‐cell leukemia/lymphoma; HLA, human leukocyte antigen; N.E., not examined.